In early 2020, Juno Therapeutics won a $1 billion jury verdict against Gilead’s Kite Pharma in connection with alleged infringement of U.S. Patent No. 7,446,190, entitled “Nucleic Acid Encoding Chimeric T Cell Receptors. In this episode, Harris Beach partner Laura Smalley discusses the implications of the Juno v. Kite pharma case, including the use of the “reasonable royalty” concept to support a large damaged award. Laura is an authority on intellectual property law and is a regular contributor to the American Intellectual Property Law Association’s Biotech Buzz newsletter as well as a presenter on regulatory and IP issues for immunotherapies, including Car-T and antibody technologies.

Related Links: 
Laura Smalley Bio - http://bit.ly/2uoTz2F
Intellectual Property Law Practice Group - https://bit.ly/30dLcCU